Bristol Myers Squibb today announced they have teamed up with renowned goalkeeper and sports commentator Kasey Keller, who is publicly sharing his personal experience with non-Hodgkin lymphoma (NHL) ...

IPA, a non-coding RNA from the CUL1 gene that stabilizes the nucleolus and supports ribosome production. Removing it ...

ONC, extended its collaboration with InSysBio to apply mechanistic translational modeling to clinical trial design. The expanded partnership focuses on refining dosing regimens and addressing safety ...

The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...

Retrospective ONCare Alliance Network data showed lower odds of new or worsened hypertension with acalabrutinib versus ibrutinib (OR 0.27; 95% CI, 0.074–0.98). Despite older age and higher baseline ...

Researchers sought to compare the safety and efficacy of pirtobrutinib monotherapy vs bendamustine plus rituximab among treatment-naïve patients with CLL/SLL.

My patient’s wife glared at me from across his bed, where she stood flanked by a half-dozen friends. My patient, lying ...

Margaret Krackeler, MD, of Kaiser Permanente Northern California, discusses the growing role of real-world treatment data in CLL and other cancers.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

Good afternoon, and thank you for joining us on our fourth quarter and full year earnings call. As shown on Slide 3, in the ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript February 5, 2026 Adaptive Biotechnologies ...

Eli Lilly and Company (NYSE:LLY) Q4 2025 Earnings Call Transcript February 4, 2026 Eli Lilly and Company beats earnings ...